Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 129 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Levetiracetam, Keppra Clear all
Completed Phase 2 Interventional Results available

Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability

NCT02002819
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
levetiracetam
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Phase 2 Interventional

Levetiracetam (Keppra) Tolerability in Cocaine Abusing Methadone-maintained Patients.

NCT00593125
View directory record Official record
Conditions
Cocaine Dependence, Opioid Dependence
Interventions
levetiracetam
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Keppra and Clonidine in the Treatment of Tics

NCT00370838
View directory record Official record
Conditions
Tic Disorders, Tourette Syndrome
Interventions
Levetiracetam, Clonidine
Drug
Lead sponsor
Harvey S. Singer
Other
Eligibility
7 Years to 19 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2011 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fed Conditions

NCT01132352
View directory record Official record
Conditions
Healthy
Interventions
Levetiracetam
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 13, 2010 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder

NCT00265109
View directory record Official record
Conditions
Body Dysmorphic Disorder
Interventions
Levetiracetam
Drug
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Sep 28, 2026, 4:09 PM EDT
Not listed Phase 2 Interventional

Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE)

NCT04004702
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Levetiracetam
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Not applicable Interventional Results available

Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia

NCT02647437
View directory record Official record
Conditions
Schizophrenia
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Not applicable Interventional Results available

Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH

NCT01137110
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Brief LEV, Extended LEV
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Not applicable Interventional

A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy

NCT00361010
View directory record Official record
Conditions
Epilepsy, Childhood Absence Epilepsy, Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
4 Years to 10 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

Therapy for Children With Advanced Stage Neuroblastoma

NCT01857934
View directory record Official record
Conditions
Neuroblastoma
Interventions
cyclophosphamide, topotecan, hu14.18K322A, peripheral blood stem cell harvest, surgical resection, cisplatin, etoposide, doxorubicin, vincristine, busulfan, melphalan, peripheral blood stem cell transplantation, natural killer cell infusion, radiation therapy, GM-CSF, G-CSF, mesna, levetiracetam, interleukin-2, Isotretinoin, CliniMACS
Drug · Biological · Procedure + 2 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effects of Levetiracetam on Alcohol Dependent Subjects

NCT00325182
View directory record Official record
Conditions
Alcoholism
Interventions
Levetiracetam, Historical controls
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
21 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 28, 2026, 4:09 PM EDT
Recruiting Phase 2 Interventional

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

NCT07130786
View directory record Official record
Conditions
Seizures, Primary Motor Cortex, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Adult, Brain Metastases From Extra-cranial Solid Tumors
Interventions
Levetiracetam (Keppra)
Drug
Lead sponsor
Ayal A. Aizer, MD
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting Conditions

NCT00826865
View directory record Official record
Conditions
Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures

NCT00152516
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
levetiracetam (LEV)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 16 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
38
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Phase 2 Interventional

A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.

NCT00156689
View directory record Official record
Conditions
Chronic Idiopathic Axonal Polyneuropathy
Interventions
levetiracetam
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy

NCT00505934
View directory record Official record
Conditions
Epilepsy
Interventions
Levetiracetam
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
1 Month to 4 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
San Diego, California • Buffalo, New York • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Sep 28, 2026, 4:09 PM EDT
Recruiting Phase 2 Interventional

A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

NCT05610085
View directory record Official record
Conditions
Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Seizure Newborn
Interventions
Levetiracetam Injection, Phenobarbital Sodium Injection
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 1 Month
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
San Diego, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 28, 2026, 4:09 PM EDT
Terminated Phase 4 Interventional Results available

Seizure Prophylaxis in Aneurysm Repair

NCT01974700
View directory record Official record
Conditions
Intracranial Aneurysms, Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 28, 2026, 4:09 PM EDT
Recruiting Phase 2 Interventional

Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

NCT05824728
View directory record Official record
Conditions
Parkinson Disease Psychosis
Interventions
AGB101
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

NCT00419393
View directory record Official record
Conditions
Epilepsy
Interventions
Keppra XR (Levetiracetam XR)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
12 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
16
States / cities
Dothan, Alabama • Northport, Alabama • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Results available

Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention

NCT00618436
View directory record Official record
Conditions
Traumatic Brain Injury, Subarachnoid Hemorrhage
Interventions
Levetiracetam, Phenytoin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2014 · Synced Sep 28, 2026, 4:09 PM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Keppra on Thinking, Emotions, and Balance in Elderly Healthy Volunteers

NCT00221988
View directory record Official record
Conditions
Epilepsy
Interventions
Levetiracetam (Keppra)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
65 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 28, 2026, 4:09 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia

NCT03034356
View directory record Official record
Conditions
Schizophrenia
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 28, 2026, 4:09 PM EDT